Work

Abstract PO2-11-06: Anti-Müllerian hormone in Young women with breast CAncer to predict permanent loss of ovarian function after chemotherapy and anti-HER2 therapy (AMYCA): a biomarker analysis of the BETH and KAITLIN trials

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs23-po2-11-06

Authors: Matteo Lambertini, Deirdre Allegranza, Ruediger Laubender, Nadia Harbeck, Sandra Swain, Charles Geyer, Dennis Slamon, Gabriella Bobba, Chiara Lambertini, Sanne Lysbet De Haas, Eleonora Restuccia, Ines Vaz Luis, David Cameron, Ian Krop, Eric Winer, Richard Anderson

Institutions: Ospedale Policlinico San Martino, Ludwig-Maximilians-Universität München, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, MedStar Health, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, University of California, Los Angeles, Roche (Switzerland), Institut Gustave Roussy, Edinburgh Cancer Research, University of Edinburgh, Yale Cancer Center, Yale University, The Queen's Medical Research Institute

Language: English

Topic: Reproductive Biology and Fertility

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396588062

Cites:

Cited by:

Related to: 10